Focal Epilepsy

Neurology·MeSH: Epilepsy

Prevalence

700.0 / 100K

Incidence

48.0 / 100K/yr

7 drugs in development·5 companies·9 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
20 mg/day vormatrogine for 12 weeks	Praxis Precision Medicines, Inc. (PRAX)
30 mg/day vormatrogine for 12 weeks	Praxis Precision Medicines, Inc. (PRAX)
40 mg/day vormatrogine for 12 weeks	Praxis Precision Medicines, Inc. (PRAX)
rap-219	Rapport Therapeutics, Inc. (RAPP)
xen1101	Xenon Pharmaceuticals Inc. (XENE)

Phase 2(1)

Drug	Company
darigabat	Cerevel Therapeutics Holdings, Inc. (CERE)

Phase 1(1)

Drug	Company
BHV-7000	Biohaven Ltd. (BHVN)

BioSniper tracks 7 drugs in development for Focal Epilepsy across 5 companies.

There are 9 clinical trials targeting Focal Epilepsy tracked by BioSniper.

The estimated prevalence of Focal Epilepsy is approximately 700.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.